1-20 of 1385 Search Results for

drug

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Article
Journal of Health Politics, Policy and Law (1 February 1979) 4 (1): 87–108.
Published: 01 February 1979
...James Christopher Anthony The Controlled Substances Act (CSA) is the prevailing “drug abuse” control statute in the United States. Its manifest objective is to prevent or reduce drug use's “substantial and detrimental effect on the health and general welfare of the American people.” Evaluating...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2013) 38 (3): 545–571.
Published: 01 June 2013
... and efficacy information that the provinces use comes from the federal government. We interviewed drug plan officials from eight of the ten provinces and two of three territories regarding their views on the Canadian drug safety system. Here we report on the following categories: the federal drug...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1998) 23 (2): 265–290.
Published: 01 April 1998
...Mae Thamer; Niall Brennan; Rafael Semansky Six countries—Canada, France, Japan, Sweden, the United Kingdom, and the United States—were studied to compare public policies affecting the development and marketing of pharmaceuticals for rare diseases (i.e., orphan drugs). Information was obtained from...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1990) 15 (2): 357–385.
Published: 01 April 1990
...William E. McAuliffe As we enter the 1990s drug abuse has once again become a major health concern, and for the first time the drug treatment field has had to address many of the policy, regulation, and planning issues resulting from cost inflation that have become commonplace in other parts of...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2005) 30 (4): 719–750.
Published: 01 August 2005
...Helene Levens Lipton; Jonathan D. Agnew; Marilyn R. Stebbins; Angela Kuo; R. Adams Dudley As drug costs rose in the 1990s, health maintenance organizations (HMOs) began transferring risk for prescription drug expenditures to physician groups. With principal-agent theory as a framework for...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2014) 39 (4): 751–780.
Published: 01 August 2014
...Thomas J. Hwang; Jerry Avorn; Aaron S. Kesselheim AbstractThe US Food and Drug Administration (FDA) uses rulemaking as one of its primary tools to protect the public health and implement laws enacted by Congress and the president. Because of the many effects that these rules have on social welfare...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2010) 35 (6): 961–997.
Published: 01 December 2010
...Thomas Rice; Janet Cummings The Medicare prescription drug benefit relies on private insurers. In most states, there are nearly fifty competing insurance plans available. The sheer number of choices makes it extremely difficult for Medicare beneficiaries, many of whom must cope with declining...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2013) 38 (6): 1081–1102.
Published: 01 December 2013
... measurement of more meaningful clinical end points and increased engagement between manufacturers, drug regulators, and payers. A consistent finding in studies of reimbursement decisions is that economic considerations have been influential, second only to the strength of the clinical evidence for the drug of...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1979) 4 (2): 155–175.
Published: 01 April 1979
...Michael Ira Smith; Albert I. Wertheimer In 1973 the federal government moved to limit drug reimbursement to providers in federally sponsored or supported programs, to the lowest cost at which the drug is generally and consistently available unless a difference in therapeutic effect can be...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2013) 38 (3): 573–597.
Published: 01 June 2013
... also contribute to economic efficiency by creating transparency as the foundation of competitive generic drug markets, reducing transaction costs, and favoring trade. The law in most countries requires manufacturers to designate pharmaceuticals with INNs in labeling and advertising. Generic...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1982) 7 (2): 521–523.
Published: 01 April 1982
...Peter Temin Milton Silverman, Philip R. Lee, and Mia Lydecker, Pills and the Public Purse: The Routes to National Drug Insurance (Berkeley: University of California Press, 1981), 232 pp., $15.95 hardbound Copyright © 1982 by the Department of Health Administration, Duke University Press 1982...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2000) 25 (4): 653–688.
Published: 01 August 2000
...William J. Moore; Karen Gutermuth; Etienne E. Pracht Aggregate pooled cross-sectional and time-series annual state data for 1985 to 1992 were used to estimate the systemwide effects of retrospective drug utilization review programs (Retro-DUR) on Medicaid drug and nondrug outcomes. The results...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2001) 26 (6): 1261–1290.
Published: 01 December 2001
...Shama Gamkhar; Shao-Chee Sim Are the federal Alcohol and Drug Abuse (ADA) block grant funds substituting for or supplementing state and local government spending on substance abuse?Using panel data on state and local government substance abuse programs, this study explores the fiscal effects of...
Journal Article
Journal of Health Politics, Policy and Law (1 August 1994) 19 (4): 922–924.
Published: 01 August 1994
...Kenneth I. Kaitin Milton Silverman, Mia Lydecker, and Philip R. Lee. Bad Medicine: The Prescription Drug Industry in the Third World . Stanford, CA: Stanford University Press, 1992. 358 pp. $29.95 cloth. Copyright © 1994 by Duke University Press 1994 922 Journal of Health Politics, Policy and...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2000) 25 (3): 595–597.
Published: 01 June 2000
...Drew Humphries Laura E. Gomez. Misconceiving Mothers: Legislators, Prosecutors, and the Politics of Prenatal Drug Exposure . Philadelphia: Temple University Press, 1997. 256 pp. $59.95 cloth; $19.95 paper. © 2000 by Duke University Press 2000 JHPPL 25.3-05.BkRevs (565-612) 5/12/00 11:59 AM...
Journal Article
Journal of Health Politics, Policy and Law (1 August 1989) 14 (4): 719–740.
Published: 01 August 1989
..., while similar programs have been instituted in other countries where intravenous drug use has also contributed to the spread of HIV infection and AIDS. Copyright © 1989 by Duke University Press 1989 References American Medical Association, Council on Scientific Affairs. 1988 . Reducing Transmission...
Journal Article
Journal of Health Politics, Policy and Law (1 August 1996) 21 (4): 751–768.
Published: 01 August 1996
... on the intended services or use budgetary strategies to appear to be in compliance with maintenance-of-effort provisions but then reallocate block grant funds from the targeted program. We studied the effect of the Alcohol, Drug Abuse, and Mental Health block grant program on state substance abuse...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2004) 29 (3): 397–430.
Published: 01 June 2004
...Mary K. Olson This article examines the effects of the user fee reform on the speed of drug review in the U.S. Food and Drug Administration. The results show that even after controlling for increased agency resources, the reform reduced review times among new-drug approvals by 34 percent (95...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2004) 29 (3): 431–442.
Published: 01 June 2004
...Daniel Carpenter © 2004 by Duke University Press 2004 Carpenter, Daniel P. 2000 . Protection without Capture: Drug Approval by a Politically Responsive, Bayesian Regulator . Robert Wood Johnson Foundation Scholars in Health Policy Working Paper No. 13. ———. 2002 . Groups, the Media, Agency...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2004) 29 (3): 443–450.
Published: 01 June 2004
...Mary K. Olson © 2004 by Duke University Press 2004 DiMasi, J. A. 1996 . A New Look at United States Drug Development and Approval Times. American Journal of Therapeutics 3 : 1 -11. Dranove, D., and D. Meltzer. 1994 . Do Important Drugs Reach the Market Sooner? RAND Journal of Economics...